CN113710672B - 用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物 - Google Patents

用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物 Download PDF

Info

Publication number
CN113710672B
CN113710672B CN202080030189.2A CN202080030189A CN113710672B CN 113710672 B CN113710672 B CN 113710672B CN 202080030189 A CN202080030189 A CN 202080030189A CN 113710672 B CN113710672 B CN 113710672B
Authority
CN
China
Prior art keywords
methyl
hexahydro
pyrazin
amino
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030189.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113710672A (zh
Inventor
朱伟
张志伟
张志森
沈宏
刘永福
刘亚飞
刘海侠
寇步雨
F·戴伊
戴略
朱丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN113710672A publication Critical patent/CN113710672A/zh
Application granted granted Critical
Publication of CN113710672B publication Critical patent/CN113710672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080030189.2A 2019-04-09 2020-04-07 用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物 Active CN113710672B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081900 2019-04-09
CN2019081900 2019-04-09
CNPCT/CN2019/121598 2019-11-28
CN2019121598 2019-11-28
CN2020078225 2020-03-06
CNPCT/CN2020/078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
CN113710672A CN113710672A (zh) 2021-11-26
CN113710672B true CN113710672B (zh) 2025-01-03

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030189.2A Active CN113710672B (zh) 2019-04-09 2020-04-07 用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物

Country Status (19)

Country Link
US (1) US20220340597A1 (https=)
EP (1) EP3953356B1 (https=)
JP (1) JP7692838B2 (https=)
KR (1) KR20210149163A (https=)
CN (1) CN113710672B (https=)
AU (1) AU2020272467A1 (https=)
BR (1) BR112021020297A2 (https=)
CA (1) CA3135129A1 (https=)
CL (1) CL2021002621A1 (https=)
CO (1) CO2021013166A2 (https=)
CR (1) CR20210513A (https=)
IL (1) IL286870A (https=)
MA (1) MA55594A (https=)
MX (1) MX2021012223A (https=)
PE (1) PE20212178A1 (https=)
PH (1) PH12021552533A1 (https=)
SG (1) SG11202110401WA (https=)
TW (1) TW202104230A (https=)
WO (1) WO2020207991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728959B (zh) * 2019-11-12 2024-11-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201A (zh) * 2011-01-12 2014-02-05 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56747B1 (sr) 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP2022501401A (ja) * 2018-09-27 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのヘテロシクリル化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201A (zh) * 2011-01-12 2014-02-05 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物

Also Published As

Publication number Publication date
PH12021552533A1 (en) 2022-06-20
CN113710672A (zh) 2021-11-26
AU2020272467A1 (en) 2021-10-14
EP3953356A1 (en) 2022-02-16
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
CR20210513A (es) 2021-11-02
IL286870A (en) 2021-10-31
TW202104230A (zh) 2021-02-01
WO2020207991A1 (en) 2020-10-15
KR20210149163A (ko) 2021-12-08
BR112021020297A2 (pt) 2021-12-14
CA3135129A1 (en) 2020-10-15
PE20212178A1 (es) 2021-11-09
EP3953356B1 (en) 2023-07-26
US20220340597A1 (en) 2022-10-27
MA55594A (fr) 2022-02-16
JP2022527588A (ja) 2022-06-02
JP7692838B2 (ja) 2025-06-16
CL2021002621A1 (es) 2022-05-13
MX2021012223A (es) 2021-11-03
EP3953356C0 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
CN113710672B (zh) 用于治疗自身免疫性疾病的六氢-1H-吡嗪并[1,2-a]吡嗪化合物
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
WO2024188209A1 (zh) 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
CN114728976B (zh) 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
KR20170005870A (ko) Jak 억제제인 5-클로로-2-다이플루오로메톡시페닐 피라졸로피리미딘 화합물
WO2019238629A1 (en) Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
CN114599652B (zh) 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
CN117980297A (zh) 作为egfr抑制剂的取代的氨基吡啶化合物
US12503471B2 (en) Triazatricycle compounds for the treatment of autoimmune disease
CN114761406B (zh) 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
HK40055574A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
HK40055574B (zh) 用於治疗自身免疫性疾病的六氢-1h-吡嗪幷[1，2- a]吡嗪化合物
CA3285578A1 (en) New e3 ubiquitin ligase ligand, protein degradation agent and use thereof
HK40068905A (en) Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
HK40069883A (en) Triazatricycle compounds for the treatment of autoimmune disease
HK40068905B (zh) 用於治疗自身免疫性疾病的氢吡嗪并[1，2-d][1，4]二氮杂䓬化合物
HK40071775A (en) Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
EA052162B1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
HK1249502B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
HK1241873A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1201265B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1201265A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055574

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant